Fennec Pharmaceuticals Inc. The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina on behalf of investors who purchased Fennec Pharmaceuticals Inc. (NASDAQ: FENC) securities between May 28, 2021 and November 26, 2021.
According to the Fennec lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application (“NDA”); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
“Fennec Pharmaceuticals Inc.”
If you suffered a loss in Fennec you have until April 11, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.